Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.

MLA

Leung-Hagesteijn, Chungyee, et al. “Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.” Cancer Cell, vol. 28, no. 4, Oct. 2015, pp. 541–42. EBSCOhost, https://doi.org/10.1016/j.ccell.2015.09.010.

APA

Leung-Hagesteijn, C., Erdmann, N., Cheung, G., Keats, J. J., Stewart, A. K., Reece, D. E., Chung, K. C., & Tiedemann, R. E. (2015). Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma. Cancer Cell, 28(4), 541–542. https://doi.org/10.1016/j.ccell.2015.09.010

Chicago

Leung-Hagesteijn, Chungyee, Natalie Erdmann, Grace Cheung, Jonathan J. Keats, A. Keith Stewart, Donna E. Reece, Kim Chan Chung, and Rodger E. Tiedemann. 2015. “Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma.” Cancer Cell 28 (4): 541–42. doi:10.1016/j.ccell.2015.09.010.